TY - JOUR
T1 - Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions 1, 6, 7, 8 and 10
AU - KAWASAKI, ANDREW M.
AU - KNAPP, RICHARD J.
AU - WALTON, AMANDA
AU - WIRE, WILLIAM S.
AU - ZALEWSKA, TERESA
AU - YAMAMURA, HENRY I.
AU - PORRECA, FRANK
AU - BURKS, THOMAS F.
AU - HRUBY, VICTOR J.
PY - 1993/11
Y1 - 1993/11
N2 - Structural, stereochemical, stereoelectronic and conformational requirements for biological activity of dynorphin A1–11‐NH2 analogues at opioid receptors were explored by substitution of Tyr1, Arg6, Arg7, Ile8 and Pro10 with other amino acid residues. Interestingly, substitution of Tyr1 with Nα‐Ac‐Tyrl, D‐Tyr1, Phe1 or p‐BrPhe1 led to analogues that were quite potent at κ opioid receptors, and additional substitution of Ile8with D‐Ala8 and/or Pro10 with D‐Pro10 retained high potency in brain binding assay: [Nα‐Ac‐Tyr1]‐ (1), [D‐Tyr1]‐ (2) [Phe1]‐ (3), [Phe1. D‐Ala8]‐ (5), [p‐BrPhe1, D‐Alas]‐ (6), [Phe1, D‐Pro10]‐ (7) and [Phe1, D‐Ala8, D‐Pro10]‐Dyn A1–11‐NH2 (8) had IC50(nM) binding affinities of 13.2, 18.6, 1.64, 1.26, 1.84, 2.44 and 1.62 nM, respectively. The D‐Phe1 analogue 4, however, was only weakly active (610 nM). All of the analogues except 4 were modestly selective for κ vs. μ guinea pig brain opioid receptor (11‐ to 88–fold) and quite selective for κ vs. δ receptors (65–576). However, all of the analogues appeared to have very low or essentially no activity in the guinea pig ileum and mouse vas deference functional bioassays, and one analogue, 5, appeared to have weak antagonist activities. On the other hand, if constrained amino acids such as β‐methylphenylalanine or 1,2,3,4‐tetrahydroisoquinoline carboxylic acid, and hydroxyproline were placed in the 1 position, inactive analogues or analogues with greatly reduced potency and biological activity were obtained (compounds 12–14). It had previously been suggested that the Arg6 and Arg7 residues were critical for biological activity. However, when we replace either one of these residues, [Nle6]Dyn A1–11 (9) and [Nle7]Dyn A1–11‐NH2 (10) were both highly potent binders in κ receptor binding studies (IC50= 0.95 and 0.43 nM, respectively), and interestingly also were potent in μ and δ binding studies. Furthermore, both of the analogues were modestly potent in the GPI and MVD assays (94, 65 nM; 31, 81 nM, respectively). These results demonstrate that basic residues at positions 6 and 7 in dynorphin are not very important for binding to κ opioid receptors. Finally, many of the compounds reported here showed high selectivity for central vs. peripheral κ opioid receptors, with compound 4 being the most selective (63 000‐fold).
AB - Structural, stereochemical, stereoelectronic and conformational requirements for biological activity of dynorphin A1–11‐NH2 analogues at opioid receptors were explored by substitution of Tyr1, Arg6, Arg7, Ile8 and Pro10 with other amino acid residues. Interestingly, substitution of Tyr1 with Nα‐Ac‐Tyrl, D‐Tyr1, Phe1 or p‐BrPhe1 led to analogues that were quite potent at κ opioid receptors, and additional substitution of Ile8with D‐Ala8 and/or Pro10 with D‐Pro10 retained high potency in brain binding assay: [Nα‐Ac‐Tyr1]‐ (1), [D‐Tyr1]‐ (2) [Phe1]‐ (3), [Phe1. D‐Ala8]‐ (5), [p‐BrPhe1, D‐Alas]‐ (6), [Phe1, D‐Pro10]‐ (7) and [Phe1, D‐Ala8, D‐Pro10]‐Dyn A1–11‐NH2 (8) had IC50(nM) binding affinities of 13.2, 18.6, 1.64, 1.26, 1.84, 2.44 and 1.62 nM, respectively. The D‐Phe1 analogue 4, however, was only weakly active (610 nM). All of the analogues except 4 were modestly selective for κ vs. μ guinea pig brain opioid receptor (11‐ to 88–fold) and quite selective for κ vs. δ receptors (65–576). However, all of the analogues appeared to have very low or essentially no activity in the guinea pig ileum and mouse vas deference functional bioassays, and one analogue, 5, appeared to have weak antagonist activities. On the other hand, if constrained amino acids such as β‐methylphenylalanine or 1,2,3,4‐tetrahydroisoquinoline carboxylic acid, and hydroxyproline were placed in the 1 position, inactive analogues or analogues with greatly reduced potency and biological activity were obtained (compounds 12–14). It had previously been suggested that the Arg6 and Arg7 residues were critical for biological activity. However, when we replace either one of these residues, [Nle6]Dyn A1–11 (9) and [Nle7]Dyn A1–11‐NH2 (10) were both highly potent binders in κ receptor binding studies (IC50= 0.95 and 0.43 nM, respectively), and interestingly also were potent in μ and δ binding studies. Furthermore, both of the analogues were modestly potent in the GPI and MVD assays (94, 65 nM; 31, 81 nM, respectively). These results demonstrate that basic residues at positions 6 and 7 in dynorphin are not very important for binding to κ opioid receptors. Finally, many of the compounds reported here showed high selectivity for central vs. peripheral κ opioid receptors, with compound 4 being the most selective (63 000‐fold).
KW - constrained dynorphin A analogues
KW - dynorphin A
KW - dynorphin A analogues
KW - dynorphin A antagonist
KW - stereochemical and stereoelectronic effects
KW - structure‐activity relationships
UR - http://www.scopus.com/inward/record.url?scp=0027364033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027364033&partnerID=8YFLogxK
U2 - 10.1111/j.1399-3011.1993.tb00148.x
DO - 10.1111/j.1399-3011.1993.tb00148.x
M3 - Article
C2 - 7906258
AN - SCOPUS:0027364033
SN - 0367-8377
VL - 42
SP - 411
EP - 419
JO - International journal of peptide and protein research
JF - International journal of peptide and protein research
IS - 5
ER -